Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pediatrix Medical (MD)

Pediatrix Q4 EPS $0.40 vs $0.36; 2026 Adjusted EBITDA outlook $280M-$300M

Mixed Impact 3 of 5 earnings Written later

Pediatrix Medical Group reported fourth-quarter 2025 net income of $33.7 million, or $0.40 per diluted share, up from $0.36 a year earlier, while net revenue fell to $493.8 million from $502.4 million and Adjusted EBITDA fell to $65.8 million from $68.7 million. For full-year 2025, net income was $165.4 million, or $1.94 per share, compared with a net loss in 2024, and the company preliminarily expects 2026 Adjusted EBITDA of $280 million to $300 million.

Key points

  • Q4 2025 net revenue of $493.8 million vs $502.4 million in Q4 2024; same-unit revenue grew 4.0 percent, offset by practice dispositions
  • Q4 2025 net income of $33.7 million, or $0.40 per diluted share, vs $30.5 million, or $0.36, in Q4 2024; Adjusted EPS was $0.50 vs $0.51
  • Full-year 2025 net income of $165.4 million ($1.94 per share) vs a net loss of $99.1 million ($1.19 per share) in 2024
  • Preliminary 2026 Adjusted EBITDA outlook of $280 million to $300 million

The filing

CompanyPediatrix Medical (MD)
Form8-K, current report
Filed with the SECFeb 19, 2026, 6:50 AM ET
Accession number0001193125-26-058063

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 19, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.